Abstract
Malignant fibrous histiocytoma (MFH) originates from primitive mesenchymal cells and has the capacity for dual differentiation into histiocytes and fibroblasts. MFH occurring as a secondary malignancy following radio-chemotherapy is rare and its exact incidence is not yet known. Here we report a case of a 42-year-old man who developed MFH in his right knee over a period of more than 10 years after radio (44 Gy)-chemotherapy to treat Hodgkin's lymphoma. After the diagnosis the patient did not return and was lost to follow-up. This is a rare case with unusual presentation, and it highlights the importance of the awareness and prevention of such secondary tumors.
MeSH terms
-
Adult
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Bleomycin / adverse effects
-
Bone Neoplasms / etiology*
-
Chemotherapy, Adjuvant
-
Dacarbazine / adverse effects
-
Doxorubicin / adverse effects
-
Histiocytoma, Malignant Fibrous / etiology*
-
Hodgkin Disease / drug therapy
-
Hodgkin Disease / pathology
-
Hodgkin Disease / radiotherapy
-
Hodgkin Disease / therapy*
-
Humans
-
Male
-
Mechlorethamine / adverse effects
-
Muscle Neoplasms / etiology*
-
Neoplasms, Radiation-Induced / etiology
-
Prednisone / adverse effects
-
Procarbazine / adverse effects
-
Radiotherapy, Adjuvant
-
Vinblastine / adverse effects
-
Vincristine / adverse effects
Substances
-
Bleomycin
-
Procarbazine
-
Mechlorethamine
-
Vincristine
-
Vinblastine
-
Dacarbazine
-
Doxorubicin
-
Prednisone
Supplementary concepts
-
ABVD protocol
-
MOPP protocol